2022
Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Savinkina A, Paltiel A, Ross J, Gonsalves G. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis. Open Forum Infectious Diseases 2022, 9: ofac637. PMID: 36589482, PMCID: PMC9792084, DOI: 10.1093/ofid/ofac637.Peer-Reviewed Original ResearchCost-effectiveness analysisTrade-offs implicitSevere diseaseDecision analytic modelAllocation decisionsPay thresholdsPolicy strategiesUnvaccinated patientsVaccination statusHigh riskTreatment effectivenessHigh-risk individualsAllocation strategyPopulation-level strategiesWillingnessFurther priorityDrug costsSensitivity analysisCostRitonavir treatmentUnvaccinated personsVaccinated adultsPatient populationClinical trialsLower risk
2021
Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021
Paltiel AD, Schwartz JL. Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. Annals Of Internal Medicine 2021, 174: m21-2965. PMID: 34461034, PMCID: PMC8422997, DOI: 10.7326/m21-2965.Peer-Reviewed Original ResearchConceptsVaccine effectivenessVaccination coverageAsymptomatic testingBroad vaccination coverageLess frequent testingCOVID-19 prevention strategiesHigh vaccination ratesBase-case assumptionsFall 2021COVID-19 incidenceUnvaccinated personsVaccination ratesDisease progressionHypothetical cohortEffective vaccineAsymptomatic transmissionPrevention strategiesViral transmissionCumulative casesNonpharmaceutical interventionsDrug abuseCumulative infectionsSafe returnVaccinePopulation coverage